Novartis (NOTA) Stock Forecast & Price Target

Compare

23 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NOTA Analyst Ratings

Hold

1 Buy

4 Hold

1 Sell

Based on 6 analysts giving stock ratings to

Novartis

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NOTA Stock 12 Month Forecast

Average Price Target

€116.31

▼(-12.55% Downside)

Based on 6 Wall Street analysts offering 12 month price targets for Novartis in the last 3 months. The average price target is €116.31 with a high forecast of €151.98 and a low forecast of €94.57. The average price target represents a -12.55% change from the last price of €133.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"93":"€93","152":"€152","107.75":"€107.8","122.5":"€122.5","137.25":"€137.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":151.9829982,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€151.98</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":116.3092111225,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€116.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":94.56719888,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€94.57</span>\n  </div></div>","useHTML":true}}],"tickPositions":[93,107.75,122.5,137.25,152],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,127.5,129.38330755384615,131.2666151076923,133.14992266153845,135.0332302153846,136.91653776923076,138.7998453230769,140.6831528769231,142.56646043076924,144.4497679846154,146.33307553846154,148.2163830923077,150.09969064615385,{"y":151.9829982,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,127.5,126.63917008634616,125.77834017269231,124.91751025903847,124.05668034538462,123.19585043173078,122.33502051807693,121.47419060442307,120.61336069076923,119.75253077711538,118.89170086346154,118.03087094980769,117.17004103615385,{"y":116.3092111225,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,127.5,124.96670760615385,122.4334152123077,119.90012281846154,117.36683042461539,114.83353803076923,112.30024563692308,109.76695324307693,107.23366084923077,104.70036845538462,102.16707606153847,99.63378366769231,97.10049127384616,{"y":94.56719888,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":97.992,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":99.447,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":100.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.5,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":95.2,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":110.5,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":106.5,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":108.5,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":109.5,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":117,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":127.5,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€151.98

Average Price Target€116.31

Lowest Price Target€94.57

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Steve Scala

TD Cowen

€135.1→€151.98

Hold

14.27%

Upside

Reiterated

02/17/26

Novartis: Vanrafia’s Mixed Phase III Data and Modest EPS Growth Support Balanced Risk‑Reward and Hold Rating

Kerry Holford

Berenberg Bank

€97.94

Hold

-26.36%

Downside

Reiterated

01/06/26

Berenberg Bank Sticks to Their Hold Rating for Novartis (NVS)

Emily Field

Barclays

Hold

―

Upgraded

01/06/26

Novartis upgraded to Equal Weight from Underweight at BarclaysNovartis upgraded to Equal Weight from Underweight at Barclays

Rajesh Kumar

HSBC

€89.5→€94.57

Sell

-28.90%

Downside

Reiterated

12/10/25

Novartis price target raised to $112 from $106 at HSBCNovartis price target raised to $112 from $106 at HSBC

Thibault Boutherin

Morgan Stanley

€114.83→€120.74

Buy

-9.22%

Downside

Upgraded

12/03/25

Novartis price target raised to $143 from $136 at Morgan StanleyNovartis price target raised to $143 from $136 at Morgan Stanley

Richard Vosser

J.P. Morgan

Hold

―

Reiterated

11/20/25

J.P. Morgan Sticks to Its Hold Rating for Novartis (NVS)

James Quigley

Goldman Sachs

€100.48→€99.63

Sell

-25.09%

Downside

Downgraded

09/12/25

Novartis (NVS) was downgraded to a Sell Rating at Goldman Sachs

Sachin Jain

Bank of America Securities

€121.78

Hold

-8.44%

Downside

Reiterated

06/02/25

Novan (NOVN) Gets a Hold from Bank of America Securities

Unknown Analyst

Edgewater Research

Not Ranked

Edgewater Research

€97.94

Buy

-26.36%

Downside

Initiated

04/15/25

Edgewater Research starts Novartis (NVS) at OutperformEdgewater Research initiates coverage on Novartis (NYSE: NVS) with a Outperform rating and a price target of $116.00.

Peter Verdult

Exane BNP Paribas

€97.94

Buy

-26.36%

Downside

Initiated

04/15/25

Novartis initiated with an Outperform at BNP Paribas ExaneNovartis initiated with an Outperform at BNP Paribas Exane

Unknown Analyst

Argus Research

Not Ranked

Argus Research

Hold

―

Reiterated

04/04/25

we are raising our 2025 adjusted EPS estimate to $8.45 from $8.10

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Steve Scala

TD Cowen

€135.1→€151.98

Hold

14.27%

Upside

Reiterated

02/17/26

Novartis: Vanrafia’s Mixed Phase III Data and Modest EPS Growth Support Balanced Risk‑Reward and Hold Rating

Kerry Holford

Berenberg Bank

€97.94

Hold

-26.36%

Downside

Reiterated

01/06/26

Berenberg Bank Sticks to Their Hold Rating for Novartis (NVS)

Emily Field

Barclays

Hold

―

Upgraded

01/06/26

Novartis upgraded to Equal Weight from Underweight at BarclaysNovartis upgraded to Equal Weight from Underweight at Barclays

Rajesh Kumar

HSBC

€89.5→€94.57

Sell

-28.90%

Downside

Reiterated

12/10/25

Novartis price target raised to $112 from $106 at HSBCNovartis price target raised to $112 from $106 at HSBC

Thibault Boutherin

Morgan Stanley

€114.83→€120.74

Buy

-9.22%

Downside

Upgraded

12/03/25

Novartis price target raised to $143 from $136 at Morgan StanleyNovartis price target raised to $143 from $136 at Morgan Stanley

Richard Vosser

J.P. Morgan

Hold

―

Reiterated

11/20/25

J.P. Morgan Sticks to Its Hold Rating for Novartis (NVS)

James Quigley

Goldman Sachs

€100.48→€99.63

Sell

-25.09%

Downside

Downgraded

09/12/25

Novartis (NVS) was downgraded to a Sell Rating at Goldman Sachs

Sachin Jain

Bank of America Securities

€121.78

Hold

-8.44%

Downside

Reiterated

06/02/25

Novan (NOVN) Gets a Hold from Bank of America Securities

Unknown Analyst

Edgewater Research

Not Ranked

Edgewater Research

€97.94

Buy

-26.36%

Downside

Initiated

04/15/25

Edgewater Research starts Novartis (NVS) at OutperformEdgewater Research initiates coverage on Novartis (NYSE: NVS) with a Outperform rating and a price target of $116.00.

Peter Verdult

Exane BNP Paribas

€97.94

Buy

-26.36%

Downside

Initiated

04/15/25

Novartis initiated with an Outperform at BNP Paribas ExaneNovartis initiated with an Outperform at BNP Paribas Exane

Unknown Analyst

Argus Research

Not Ranked

Argus Research

Hold

―

Reiterated

04/04/25

we are raising our 2025 adjusted EPS estimate to $8.45 from $8.10

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novartis

3 Months

xxx

Success Rate

1/2 ratings generated profit

Average Return

+6.60%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +6.60% per trade.

1 Year

James QuigleyGoldman Sachs

Success Rate

1/2 ratings generated profit

Average Return

-5.45%

a rating ―

Copying James Quigley's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -5.45% per trade.

2 Years

xxx

Success Rate

1/2 ratings generated profit

Average Return

-5.45%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of -5.45% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NOTA Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NOTA has received 1 Buy Ratings, 3 Hold Ratings, and 1 Sell Ratings. NOTA average Analyst price target in the past 3 months is 116.31.

Each month's total comprises the sum of three months' worth of ratings.

NOTA Financial Forecast

NOTA Earnings Forecast

Next quarter’s earnings estimate for NOTA is €1.81 with a range of €1.68 to €1.91. The previous quarter’s EPS was €1.71. NOTA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year NOTA has Performed in-line its overall industry.

NOTA Sales Forecast

Next quarter’s sales forecast for NOTA is €11.52B with a range of €11.25B to €12.05B. The previous quarter’s sales results were €11.26B. NOTA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year NOTA has Performed in-line its overall industry.

NOTA Stock Forecast FAQ

What is DE:NOTA’s average 12-month price target, according to analysts?

Based on analyst ratings, Novartis Ag’s 12-month average price target is 116.31.

What is DE:NOTA’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for DE:NOTA, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Novartis Ag a Buy, Sell or Hold?

Novartis Ag has a consensus rating of Hold, which is based on 1 buy ratings, 4 hold ratings and 1 sell ratings.

What is Novartis Ag’s share price target?

The average share price target for Novartis Ag is 116.31. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €151.98 ,and the lowest forecast is €94.57. The average share price target represents -12.55% Decrease from the current price of €133.

What do analysts say about Novartis Ag?

Novartis Ag’s analyst rating consensus is a Hold. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of Novartis Ag?

To buy shares of DE:NOTA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Novartis (NOTA) Stock Forecast & Price Target

NOTA Analyst Ratings

NOTA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Novartis

NOTA Analyst Recommendation Trends

NOTA Financial Forecast

NOTA Earnings Forecast

NOTA Sales Forecast

NOTA Stock Forecast FAQ

Detailed List of Analyst Forecasts